ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

https://www.globenewswire.com/news-release/2022/09/19/2518720/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-Software-Version-2-1.html

https://www.globenewswire.com/news-release/2022/09/23/2521573/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Prism-Neuro-Laser-Therapy-System.html

ClearPoint Neuro Reports Third Quarter 2022 Results https://www.globenewswire.com/news-release/2022/11/08/2551424/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2022-Results.html Company Reaffirms 2022 Revenue Forecast

ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M https://seekingalpha.com/news/3904123-clearpoint-neuro-gaap-eps-of-0_15-revenue-of-5_1m • ClearPoint Neuro press release (NASDAQ:CLPT): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M. • CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M. • Cash and short-term investments totaled $40.5M as of Sept 30, 2022. • CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year. • "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett

https://www.globenewswire.com/news-release/2022/12/12/2571981/0/en/ClearPoint-Neuro-Announces-First-Patient-Enrolled-in-Glioblastoma-Trial-Using-ClearPoint-Prism-Neuro-Laser-Therapy-System-at-Sk%C3%A5ne-University-Hospital-in-Sweden.html

ClearPoint Neuro, Inc. Misses Q2 EPS by 16c https://m.investing.com/news/clearpoint-neuro-inc-misses-q2-eps-by-16c-432SI-2868428?ampMode=1

https://www.globenewswire.com/news-release/2022/06/02/2455609/25687/en/ClearPoint-Neuro-Announces-Receipt-of-MDSAP-Certification.html

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency https://www.globenewswire.com/news-release/2022/05/20/2447753/0/en/ClearPoint-Neuro-Congratulates-Partner-PTC-Therapeutics-on-Receiving-Positive-CHMP-Opinion-for-Gene-Therapy-to-Treat-AADC-Deficiency.html First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint’s SmartFlow® Cannula

https://www.fool.com/earnings/call-transcripts/2022/05/11/clearpoint-neuro-inc-clpt-q1-2022-earnings-call-tr/

ClearPoint Neuro Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/11/2441245/25687/en/ClearPoint-Neuro-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/03/2435061/25687/en/ClearPoint-Neuro-and-Higgs-Boson-Health-Announce-Collaboration.html

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1 https://www.globenewswire.com/news-release/2022/04/28/2431949/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-of-the-SmartFrame-Array-Version-1-1.html Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room

ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room https://www.globenewswire.com/news-release/2022/04/27/2430700/25687/en/ClearPoint-Neuro-Expands-Software-License-and-Research-Agreement-with-Philips-to-Power-Expansion-of-the-ClearPoint-Platform-into-the-Operating-Room.html

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results https://finance.yahoo.com/news/clearpoint-neuro-reports-fourth-quarter-210700519.html ClearPoint Neuro GAAP EPS of -$0.69 misses by $0.01, revenue of $16.3M in-line https://seekingalpha.com/news/3808108-clearpoint-neuro-gaap-eps-of-0_69-misses-0_01-revenue-of-16_3m-in-line ClearPoint Neuro press release (NASDAQ:CLPT): FY GAAP EPS of -$0.69 misses by $0.01. Revenue of $16.3M (+27.0% Y/Y) in-line.